low molecular weight heparin & ischaemic stroke

Last reviewed 01/2018

There is mixed trial evidence concerning the use of low molecular weight heparin (LMWH) in patients with acute ischaemic stroke.

Some trials suggest a reduction in mortality/dependency at six months in those treated with LMWH.

However recent evidence suggests that LMWH has no significant benefit over aspirin for acute ischaemic stroke in patients with atrial fibrillation.